Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | TP53 | P04637 | 5/20 | 0.58 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29886220 | 0.87 | ACP1 (0.56) | MAPTTP53AGPAT2LMNAPOLB | |
| SCHEMBL21750777 | 0.87 | ACP1 (0.56) | MAPTTP53AGPAT2LMNAPOLB | |
| SCHEMBL21765569 | 0.85 | MEN1 (0.63) | MAPTTP53AGPAT2LMNAPOLB | |
| SCHEMBL3237409 | 0.83 | MAPT (0.67) | MAPTTP53AGPAT2LMNAPOLB | |
| SCHEMBL20550985 | 0.81 | MAPT (0.58) | MAPTTP53AGPAT2LMNAPOLB | |
| SCHEMBL3235329 | 0.79 | MAPT (0.55) | MAPTTP53AGPAT2LMNAPOLB | |
| SCHEMBL23395448 | 0.78 | TP53 (0.47) | MAPTTP53AGPAT2LMNAPOLB | |
| SCHEMBL23586273 | 0.77 | MAPT (0.46) | MAPTTP53AGPAT2LMNAPOLB | |
| SCHEMBL433520 | 0.77 | MAPT (0.52) | MAPTTP53AGPAT2LMNAPOLB | |
| SCHEMBL21750689 | 0.76 | TP53 (0.45) | MAPTTP53AGPAT2LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503456-B2 | Substituted pyrimidines and 1,3,5-triazines as RHOJ inhibitors | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-12-23 | — | — | US | disclosed |
| EP-3825310-B1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2025-11-12 | — | — | EP | disclosed |
| US-20240391898-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2024-11-28 | — | — | US | disclosed |
| US-11952366-B2 | Substituted 1,3,5-triazines as inhibitors for a rho family of GTP-ases | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2024-04-09 | — | — | US | disclosed |
| CN-110799505-B | Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders and cardiomyopathy | 意大利学院科技基金会 | 2022-08-30 | — | — | CN | disclosed |
| US-20220242848-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2022-08-04 | — | — | US | disclosed |
| US-11198682-B2 | Substituted pyrimidines as inhibitors for a Rho family of GTP-ases | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-12-14 | — | — | US | disclosed |
| US-11198682-B2 | Substituted pyrimidines as inhibitors for a Rho family of GTP-ases | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-12-14 | — | — | US | disclosed |
| EP-3619202-B1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2021-06-30 | — | — | EP | disclosed |
| EP-3619202-B1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2021-06-30 | — | — | EP | disclosed |
| EP-3825310-A1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | Fondazione Istituto Italiano di Tecnologia (IT) | 2021-05-26 | — | — | EP | disclosed |
| EP-3825310-A1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | Fondazione Istituto Italiano di Tecnologia (IT) | 2021-05-26 | — | — | EP | disclosed |
| US-20200062733-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2020-02-27 | — | — | US | disclosed |
| US-20200062733-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952366-B2 | Substituted 1,3,5-triazines as inhibitors for a rho family of GTP-ases | CDC42, RHOA, TNK2 | MAPT 1329/4885TP53 2062/4885AGPAT2 1595/4885 |
| US-12503456-B2 | Substituted pyrimidines and 1,3,5-triazines as RHOJ inhibitors | TNK2, CDC42, CDC42BPA | MAPT 878/4885TP53 1329/4885AGPAT2 4072/4885 |
| US-20200062733-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | CDC42, RHOA, RHOT2 | MAPT 1372/4885TP53 1479/4885AGPAT2 3359/4885 |
| US-20240391898-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | CDC42, RHOA, RHOT2 | MAPT 1372/4885TP53 1479/4885AGPAT2 3359/4885 |
| US-11198682-B2 | Substituted pyrimidines as inhibitors for a Rho family of GTP-ases | CDC42, TNK2, ARHGEF1 | MAPT 1109/4885TP53 942/4885AGPAT2 2207/4885 |
| US-20220242848-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | CDC42, RHOA, RHOT2 | MAPT 1372/4885TP53 1479/4885AGPAT2 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.